6518 ORAL Subgroup results from a randomised, double-blind, multicentre phase III study of bevacizumab in combination with cisplatingemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): study BO17704
EJC SUPPLEMENTS（2007）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要